184 Matching Annotations
  1. Aug 2022
    1. Chadeau-Hyam, M., Wang, H., Eales, O., Haw, D., Bodinier, B., Whitaker, M., Walters, C. E., Ainslie, K. E. C., Atchison, C., Fronterre, C., Diggle, P. J., Page, A. J., Trotter, A. J., Ashby, D., Barclay, W., Taylor, G., Cooke, G., Ward, H., Darzi, A., … Elliott, P. (2022). SARS-CoV-2 infection and vaccine effectiveness in England (REACT-1): A series of cross-sectional random community surveys. The Lancet Respiratory Medicine, 0(0). https://doi.org/10.1016/S2213-2600(21)00542-7

    1. Kustin, T., Harel, N., Finkel, U., Perchik, S., Harari, S., Tahor, M., Caspi, I., Levy, R., Leschinsky, M., Dror, S. K., Bergerzon, G., Gadban, H., Gadban, F., Eliassian, E., Shimron, O., Saleh, L., Ben-Zvi, H., Amichay, D., Ben-Dor, A., … Stern, A. (2021). Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2 mRNA vaccinated individuals. MedRxiv, 2021.04.06.21254882. https://doi.org/10.1101/2021.04.06.21254882

    1. Lauring, A. S., Tenforde, M. W., Chappell, J. D., Gaglani, M., Ginde, A. A., McNeal, T., Ghamande, S., Douin, D. J., Talbot, H. K., Casey, J. D., Mohr, N. M., Zepeski, A., Shapiro, N. I., Gibbs, K. W., Files, D. C., Hager, D. N., Shehu, A., Prekker, M. E., Erickson, H. L., … Self, W. H. (2022). Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: Prospective observational study. BMJ, 376, e069761. https://doi.org/10.1136/bmj-2021-069761

  2. May 2022
  3. Apr 2022
    1. 🇺🇦 Meaghan Kall. (2022, January 27). NEW: 🏴󠁧󠁢󠁥󠁮󠁧󠁿 Vaccine effectiveness (symptomatic infection) data for BA.2 {Omicron’s more infectious sister} NO difference in VE between Omicron (BA.1) and BA.2 Possibly even higher VE for BA.2 but estimates overlap See full thread 🧵 from @freja_kirsebom https://t.co/bJ7uCn2cGV [Tweet]. @kallmemeg. https://twitter.com/kallmemeg/status/1486821549458001927

    1. Pérez-Then, E., Lucas, C., Monteiro, V. S., Miric, M., Brache, V., Cochon, L., Vogels, C. B. F., Cruz, E. D. la, Jorge, A., Santos, M. D. los, Leon, P., Breban, M. I., Billig, K., Yildirim, I., Pearson, C., Downing, R., Gagnon, E., Muyombwe, A., Razeq, J., … Iwasaki, A. (2021). Immunogenicity of heterologous BNT162b2 booster in fully vaccinated individuals with CoronaVac against SARS-CoV-2 variants Delta and Omicron: The Dominican Republic Experience (p. 2021.12.27.21268459). medRxiv. https://doi.org/10.1101/2021.12.27.21268459

    1. 🇺🇦 Meaghan Kall [@kallmemeg]. (2021, December 23). VACCINES Speaking of boosters, it’s not great news I’m afraid. Updated vaccine effectiveness analysis shows mRNA boosters beginning to wane from one month (week 5-9) for Omicron, and as low as 30-50% effective from 10 weeks post-booster. This effect is not seen with Delta. Https://t.co/g0tLxH3vLR [Tweet]. Twitter. https://twitter.com/kallmemeg/status/1474072056878804992

  4. Mar 2022
  5. Feb 2022
    1. ReconfigBehSci on Twitter: “RT @Gab_H_R: Effectiveness of mRNA-1273 against-Omicron and Delta variants ⚠️ The 3dose VE was 71.6% and 47.4% against Omicron infection (…” / Twitter. (n.d.). Retrieved February 22, 2022, from https://twitter.com/SciBeh/status/1496032262177136642

    1. Altarawneh, H. N., Chemaitelly, H., Hasan, M. R., Ayoub, H. H., Qassim, S., AlMukdad, S., Coyle, P., Yassine, H. M., Al-Khatib, H. A., Benslimane, F. M., Al-Kanaani, Z., Al-Kuwari, E., Jeremijenko, A., Kaleeckal, A. H., Latif, A. N., Shaik, R. M., Abdul-Rahim, H. F., Nasrallah, G. K., Al-Kuwari, M. G., … Abu-Raddad, L. J. (2022). Protection against the Omicron Variant from Previous SARS-CoV-2 Infection. New England Journal of Medicine, 0(0), null. https://doi.org/10.1056/NEJMc2200133

    1. Prof. Gavin Yamey MD MPH. (2022, January 21). His vax disinformation is at 34.55 in the video His full comments: “But people do not trust this vaccine. It’s not been through the normal trials, it’s a technology that’s not been proven as safe & effective, & now the data is coming in on the vaccine that’s showing that..” 1/3 [Tweet]. @GYamey. https://twitter.com/GYamey/status/1484668215825469445

  6. Jan 2022
    1. ReconfigBehSci. (2022, January 28). We’ve had at least 4 months of European governments tailoring policy to hospital capacity, not cases per se—So why are we still seeing arguments against the effectiveness of those policies based solely on cases, and not the actual target function? @AllysonPollock [Tweet]. @SciBeh. https://twitter.com/SciBeh/status/1487038050899222528

    1. Jennifer Cohn ✍🏻 📢. (2022, January 11). This chart says it all. If u got double vaccinated early on & are not yet boosted, ur effectively unvaccinated against Omicron infection. Thus, many adults & teens are effectively unvaccinated against infection. Kids got vaccinated recently & thus may be in a safer position. 1/ [Tweet]. @jennycohn1. https://twitter.com/jennycohn1/status/1481034404260581377

    1. Home

      Zuo, F., Abolhassani, H., Du, L., Piralla, A., Bertoglio, F., Campos-Mata, L. de, Wan, H., Schubert, M., Wang, Y., Sun, R., Cassaniti, I., Vlachiotis, S., Kumagai-Braesch, M., Andréll, J., Zhang, Z., Xue, Y., Wenzel, E. V., Calzolai, L., Varani, L., … Pan-Hammarström, Q. (2022). Heterologous immunization with inactivated vaccine followed by mRNA booster elicits strong humoral and cellular immune responses against the SARS-CoV-2 Omicron variant (p. 2022.01.04.22268755). https://doi.org/10.1101/2022.01.04.22268755

    1. Olson, S. M., Newhams, M. M., Halasa, N. B., Price, A. M., Boom, J. A., Sahni, L. C., Pannaraj, P. S., Irby, K., Walker, T. C., Schwartz, S. P., Maddux, A. B., Mack, E. H., Bradford, T. T., Schuster, J. E., Nofziger, R. A., Cameron, M. A., Chiotos, K., Cullimore, M. L., Gertz, S. J., … Randolph, A. G. (2022). Effectiveness of BNT162b2 Vaccine against Critical Covid-19 in Adolescents. New England Journal of Medicine, 0(0), null. https://doi.org/10.1056/NEJMoa2117995

    1. Carreño, J. M., Alshammary, H., Tcheou, J., Singh, G., Raskin, A., Kawabata, H., Sominsky, L., Clark, J., Adelsberg, D. C., Bielak, D., Gonzalez-Reiche, A. S., Dambrauskas, N., Vigdorovich, V., Group, P. S., Srivastava, K., Sather, D. N., Sordillo, E. M., Bajic, G., van Bakel, H., … Krammer, F. (2021). Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron. Nature. https://doi.org/10.1038/d41586-021-03846-z

  7. Dec 2021
    1. Thiruvengadam, R., Awasthi, A., Medigeshi, G., Bhattacharya, S., Mani, S., Sivasubbu, S., Shrivastava, T., Samal, S., Rathna Murugesan, D., Koundinya Desiraju, B., Kshetrapal, P., Pandey, R., Scaria, V., Kumar Malik, P., Taneja, J., Binayke, A., Vohra, T., Zaheer, A., Rathore, D., … Garg, P. K. (2021). Effectiveness of ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 infection during the delta (B.1.617.2) variant surge in India: A test-negative, case-control study and a mechanistic study of post-vaccination immune responses. The Lancet Infectious Diseases, S1473309921006800. https://doi.org/10.1016/S1473-3099(21)00680-0

  8. Nov 2021
    1. Thiruvengadam, R., Awasthi, A., Medigeshi, G., Bhattacharya, S., Mani, S., Sivasubbu, S., Shrivastava, T., Samal, S., Murugesan, D. R., Desiraju, B. K., Kshetrapal, P., Pandey, R., Scaria, V., Malik, P. K., Taneja, J., Binayke, A., Vohra, T., Zaheer, A., Rathore, D., … Garg, P. K. (2021). Effectiveness of ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 infection during the delta (B.1.617.2) variant surge in India: A test-negative, case-control study and a mechanistic study of post-vaccination immune responses. The Lancet Infectious Diseases, 0(0). https://doi.org/10.1016/S1473-3099(21)00680-0

    1. Seth Trueger. (2021, July 21). If seatbelts work so well why do we have airbags crumple zones speed limits licensing road signs traffic lights road safety engineering ambulances EMTs trauma centers brakes https://t.co/6x29wCOlwp [Tweet]. @MDaware. https://twitter.com/MDaware/status/1417680529160294401

    1. Walter, E. B., Talaat, K. R., Sabharwal, C., Gurtman, A., Lockhart, S., Paulsen, G. C., Barnett, E. D., Muñoz, F. M., Maldonado, Y., Pahud, B. A., Domachowske, J. B., Simões, E. A. F., Sarwar, U. N., Kitchin, N., Cunliffe, L., Rojo, P., Kuchar, E., Rämet, M., Munjal, I., … Gruber, W. C. (2021). Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age. New England Journal of Medicine, NEJMoa2116298. https://doi.org/10.1056/NEJMoa2116298

  9. Oct 2021
    1. Gil Feldman. (2021, October 26). @EricTopol Updated data from Israel. The booster works, without any doubt! Red (empty battery): Un-vax Light green (half battery): 2nd dose without the booster Green (full battery): With the booster https://t.co/HbZBvDMQs6 [Tweet]. @feldman_gil. https://twitter.com/feldman_gil/status/1452845319251767299

    1. Tartof, S. Y., Slezak, J. M., Fischer, H., Hong, V., Ackerson, B. K., Ranasinghe, O. N., Frankland, T. B., Ogun, O. A., Zamparo, J. M., Gray, S., Valluri, S. R., Pan, K., Angulo, F. J., Jodar, L., & McLaughlin, J. M. (2021). Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: A retrospective cohort study. The Lancet, 398(10309), 1407–1416. https://doi.org/10.1016/S0140-6736(21)02183-8

    1. Hulme, W. J., Williamson, E. J., Green, A., Bhaskaran, K., McDonald, H. I., Rentsch, C. T., Schultze, A., Tazare, J., Curtis, H. J., Walker, A. J., Tomlinson, L., Palmer, T., Horne, E., MacKenna, B., Morton, C. E., Mehrkar, A., Fisher, L., Bacon, S., Evans, D., … Goldacre, B. (2021). Comparative effectiveness of ChAdOx1 versus BNT162b2 COVID-19 vaccines in Health and Social Care workers in England: A cohort study using OpenSAFELY [Preprint]. Epidemiology. https://doi.org/10.1101/2021.10.13.21264937

    1. Higdon, M. M., Wahl, B., Jones, C. B., Rosen, J. G., Truelove, S. A., Baidya, A., Nande, A. A., ShamaeiZadeh, P. A., Walter, K. K., Feikin, D. R., Patel, M. K., Knoll, M. D., & Hill, A. L. (2021). A systematic review of COVID-19 vaccine efficacy and effectiveness against SARS-CoV-2 infection and disease [Preprint]. Epidemiology. https://doi.org/10.1101/2021.09.17.21263549

  10. Sep 2021
    1. David Dowdy on Twitter: “@NEJM joining the waning immunity debate. I’m going to push back a bit. Data from @UCSDHealth of vax effectiveness in health workers: 94% in June, 65% in July. Interpreted as ‘likely to be due to...delta and waning immunity over time, compounded by end of masking requirements.’ https://t.co/flDOfBbTs7” / Twitter. (n.d.). Retrieved September 2, 2021, from https://twitter.com/davidwdowdy/status/1433254675915157504?s=20

  11. Aug 2021
  12. Jul 2021
  13. Jun 2021
    1. Borobia, A. M., Carcas, A. J., Pérez-Olmeda, M., Castaño, L., Bertran, M. J., García-Pérez, J., Campins, M., Portolés, A., González-Pérez, M., García Morales, M. T., Arana-Arri, E., Aldea, M., Díez-Fuertes, F., Fuentes, I., Ascaso, A., Lora, D., Imaz-Ayo, N., Barón-Mira, L. E., Agustí, A., … Torvisco, J. M. (2021). Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): A multicentre, open-label, randomised, controlled, phase 2 trial. The Lancet, S0140673621014203. https://doi.org/10.1016/S0140-6736(21)01420-3

    1. Regev-Yochay, G., Amit, S., Bergwerk, M., Lipsitch, M., Leshem, E., Kahn, R., Lustig, Y., Cohen, C., Doolman, R., Ziv, A., Novikov, I., Rubin, C., Gimpelevich, I., Huppert, A., Rahav, G., Afek, A., & Kreiss, Y. (2021). Decreased Infectivity Following BNT162b2 Vaccination. SSRN Electronic Journal. https://doi.org/10.2139/ssrn.3815668

    1. Thompson, M. G., Burgess, J. L., Naleway, A. L., Tyner, H. L., Yoon, S. K., Meece, J., Olsho, L. E. W., Caban-Martinez, A. J., Fowlkes, A., Lutrick, K., Kuntz, J. L., Dunnigan, K., Odean, M. J., Hegmann, K. T., Stefanski, E., Edwards, L. J., Schaefer-Solle, N., Grant, L., Ellingson, K., … Gaglani, M. (2021). Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers—Eight U.S. Locations, December 2020–March 2021. MMWR. Morbidity and Mortality Weekly Report, 70(13), 495–500. https://doi.org/10.15585/mmwr.mm7013e3

    1. Hall, V. J., Foulkes, S., Saei, A., Andrews, N., Oguti, B., Charlett, A., Wellington, E., Stowe, J., Gillson, N., Atti, A., Islam, J., Karagiannis, I., Munro, K., Khawam, J., Group, T. S. S., Chand, M. A., Brown, C., Ramsay, M. E., Bernal, J. L., & Hopkins, S. (2021). Effectiveness of BNT162b2 mRNA Vaccine Against Infection and COVID-19 Vaccine Coverage in Healthcare Workers in England, Multicentre Prospective Cohort Study (the SIREN Study) (SSRN Scholarly Paper ID 3790399). Social Science Research Network. https://doi.org/10.2139/ssrn.3790399

  14. May 2021
    1. Eric Topol. (2021, May 1). Downgrading the concern on B.1.617, the poorly named ‘double mutant’—98% effectiveness of mRNA vaccine in an Israeli outbreak @CT_Bergstrom https://t.co/tGbuwPUmAL —Lab studies: Minimal immune evasion, expected full protection from vaccine @GuptaR_lab https://t.co/AIp24G0ROK https://t.co/AK20UWlDBD [Tweet]. @EricTopol. https://twitter.com/EricTopol/status/1388539223230140422

    1. Adam Kucharski. (2021, April 14). If populations are highly vaccinated, we’d expect a higher proportion of future cases to have been previously vaccinated (because by definition, there aren’t as many non-vaccinated people around to be infected). But what sort of numbers should we expect? A short thread... 1/ [Tweet]. @AdamJKucharski. https://twitter.com/AdamJKucharski/status/1382242089673617417

    1. Hall, V. J., Foulkes, S., Saei, A., Andrews, N., Oguti, B., Charlett, A., Wellington, E., Stowe, J., Gillson, N., Atti, A., Islam, J., Karagiannis, I., Munro, K., Khawam, J., Chand, M. A., Brown, C. S., Ramsay, M., Lopez-Bernal, J., Hopkins, S., … Heeney, J. L. (2021). COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): A prospective, multicentre, cohort study. The Lancet, 0(0). https://doi.org/10.1016/S0140-6736(21)00790-X

  15. Apr 2021
  16. Mar 2021
  17. Feb 2021
    1. Verani, J. R., Baqui, A. H., Broome, C. V., Cherian, T., Cohen, C., Farrar, J. L., Feikin, D. R., Groome, M. J., Hajjeh, R. A., Johnson, H. L., Madhi, S. A., Mulholland, K., O’Brien, K. L., Parashar, U. D., Patel, M. M., Rodrigues, L. C., Santosham, M., Scott, J. A., Smith, P. G., … Zell, E. R. (2017). Case-control vaccine effectiveness studies: Preparation, design, and enrollment of cases and controls. Vaccine, 35(25), 3295–3302. https://doi.org/10.1016/j.vaccine.2017.04.037

    1. Shen, X., Tang, H., McDanal, C., Wagh, K., Fischer, W. M., Theiler, J., Yoon, H., Li, D., Haynes, B. F., Saunders, K. O., Gnanakaran, S., Hengartner, N. W., Pajon, R., Smith, G., Dubovsky, F., Glenn, G. M., Korber, B. T., & Montefiori, D. C. (2021). SARS-CoV-2 Variant B.1.1.7 is Susceptible to Neutralizing Antibodies Elicited by Ancestral Spike Vaccines (SSRN Scholarly Paper ID 3777473). Social Science Research Network. https://papers.ssrn.com/abstract=3777473

  18. Jan 2021
    1. ReconfigBehSci. (2020, November 9). RT @peterbachmd: Relevant today: Ever sharp @nataliexdean on Vaccine Effectiveness vs Efficacy from many moons ago (i.e. About a month). Sh… [Tweet]. @SciBeh. https://twitter.com/SciBeh/status/1325889181097267200

  19. Dec 2020
  20. Oct 2020
  21. Sep 2020
    1. Natalie E. Dean en Twitter: “VACCINE EFFICACY 101: A biostatistician's primer. Ten tweets to cover:- How is vaccine efficacy calculated?- Distinguishing between infection, disease, & severe disease.- Measuring reduced infectiousness.- Vaccine efficacy vs. effectiveness!n” / Twitter. (n.d.). Twitter. Retrieved September 30, 2020, from https://twitter.com/nataliexdean/status/1310613702476017666

  22. Jul 2020
  23. Jun 2020